Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
We are optimistic about cardiovascular and neurologic benefits, but we must also monitor nutrient status, muscle mass, and bone health
Nearly 25% of the population in western countries have NAFLD and up to 6.5% fulfill the criteria of NASH ( NAFLD is considered the hepatic manifestation of metabolic syndrome ( No pharmacological therapies are approved for the treatment of NAFLD and lifestyle changes focusing on caloric restriction and weight loss constitute the general treatment recommendations
A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial
Bibliografa Wall, B.T., Stephens, F.B., Constantin-Teodosiu, D., Marimuthu, K., Macdonald, I.A
US$ 22.53
US$ 23.81
US$ 29.87
US$ 25.02
US$ 21.82
